

SUPPLEMENTARY TABLE 2. Reasons for exclusion from analysis of influenza vaccine effectiveness among outpatients with influenza-like illness and hospitalized patients with severe acute respiratory infection — eight Southern Hemisphere countries,* March–September 2025

Reason for Exclusion	No. (%) [†] of ILI patients excluded	No. (%) [§] of SARI patients excluded
Missing influenza RT-PCR results	9 (0.4)	112,466 (61.9)
Specimen collection >10 days after symptom onset	104 (4.1)	2,710 (1.5)
Vaccination <14 days before symptom onset or vaccine availability	19 (0.7)	1,327 (0.7)
Receipt of a positive SARS-CoV-2 test result	104 (4.1)	1,534 (0.8)
Age <6 months at encounter	20 (0.8)	15,134 (8.3)
Missing symptom onset date	0 (—)	436 (0.2)
Missing demographic information (sex or age)	28 (1.1)	21 (0.01)
Missing vaccination status	148 (5.8)	5,186 (2.9)
TOTAL	432 (16.9)	138,814 (76.5)

Abbreviations: ILI = influenza-like illness; RT-PCR = reverse transcription polymerase chain reaction; SARI = severe acute respiratory infection.

*Argentina, Australia, Brazil, Chile, New Zealand, Paraguay, South Africa, and Uruguay

[†]Percentage of 2,554 total ILI patients

[§]Percentage of 181,566 total SARI patients